Treating R/R MCL is a clinical challenge, and Bruton kinase (BTK) inhibitors or anti-Bcl2 agents (venetoclax) can achieve a high objective response rate, though the survival is short and unsatisfactory. Here, BCL2 is linked to mantle cell lymphoma.